PURPOSE: To investigate the effect of intravitreal @entity2995 injection on the resolution of @entity5173 ( @entity5173 ), and its correlation with visual outcome after scleral buckle (SB) surgery. METHODS: A prospective consecutive case series was conducted in @entity1 who underwent SB surgery for macula-off @entity1713 ( @entity1713 ) at Farabi Eye Hospital from February 1, 2012 to August 30, 2013. Exclusion criteria included previous ocular surgery (e.g. primary surgical failure) except @entity231 surgery, recurrent @entity1713 , macular hole, epiretinal membrane, proliferative @entity1715 grade C, history of @entity130 , other @entity989 , and @entity6 . @entity1 were assigned to two groups. In group 1, @entity1 received 2 mg of intravitreal @entity2995 injection at the end of surgery while @entity1 in group 2 received intravitreal balanced saline solution for balancing the intraocular pressure (IOP). @entity1 were followed up at 1 day, 1 week, 1 month, 2 months and 3 months after the surgery by best-corrected visual acuity (BCVA), slitlamp examination, indirect ophthalmoscopy and optical coherence tomography (OCT). OCT (Heidelberg Engineering, Heidelberg, Germany) was used at all visits except day 1 after the surgery. Student's t test and   (2) tests were used for comparisons; p value  <= 0.05 was considered significant. RESULTS: Sixty-two eyes of 62 @entity1 were enrolled in the study. There were 33 male @entity1 (53%) and 29 female @entity1 (47%). The average age was 43.8 years (18-72 years). The mean duration of symptoms was 34.7    46.8 days. There were 29 eyes in group 1 and 33 eyes in group 2. Twelve weeks after the operation, 25 @entity1 (40%) had @entity5173 beneath the macula, but there was no significant difference (p = 0.24,   (2) test) between the two groups. Improvement in BCVA in both groups was statistically significant (p  <= 0.001) but did not differ between the two groups (p = 0.09) apart from week 12, in which the improvement in group 1 was significantly higher (p = 0.03). The incidence of @entity1103 did not differ in a statistically significant way between the groups (p = 0.19). IOP in 4 (15%) @entity1 in group 1 rose above 21 mm Hg but responded quickly to 2 weeks of topical antiglaucoma medication. There was no @entity231 progression in either group. There was no correlation between the incidence of persistent @entity5173 and the extent of detachment in both groups (p = 0.83). There was no surgical failure or redetachment in either group during the study period. CONCLUSION: Single-dose intravitreal @entity2713 may increase the final BCVA in macula-off @entity1713 @entity1 despite persistent @entity5173 , suggesting the anti-inflammatory role of this drug.

Influence of intravitreal @entity2995 injection in scleral buckling surgery for macula-off XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity2995 :: ('MESH:D014222', 'Chemical') :: ['triamcinolone acetonide'] @entity1715 :: ('MESH:D018630', 'Disease') :: ['vitreoretinopathy'] @entity231 :: ('MESH:D002386', 'Disease') :: ['cataract'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes mellitus'] @entity1713 :: ('MESH:D012163', 'Disease') :: ['RRD', 'rhegmatogenous retinal detachment', 'retinal detachment'] @entity1103 :: ('MESH:D008269', 'Disease') :: ['cystoid macular edema'] @entity5173 :: ('MESH:D065634', 'Disease') :: ['SRF', 'subretinal fluid'] @entity989 :: ('MESH:D012164', 'Disease') :: ['retinal diseases'] @entity130 :: ('MESH:D014947', 'Disease') :: ['trauma'] @entity2713 :: ('MESH:D014221', 'Chemical') :: ['triamcinolone']
@entity1713 :: (MESH:D012163,Disease) :: ['retinal detachment']
